A 6-week, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of the Efficacy and Safety of Cariprazine in Pediatric Subjects (10 to 17 Years of Age) in the Treatment of Depressive Episodes Associated With Bipolar I Disorder
Latest Information Update: 24 Jun 2024
At a glance
- Drugs Cariprazine (Primary)
- Indications Bipolar I disorders
- Focus Adverse reactions; Registrational; Therapeutic Use
- Sponsors Allergan
- 18 Jun 2024 Primary endpoints has been amended.
- 18 Jun 2024 Planned End Date changed from 29 Jan 2025 to 10 Mar 2027.
- 18 Jun 2024 Planned primary completion date changed from 29 Jan 2025 to 10 Mar 2027.